Skip to main content
SpringerLink
Log in

Chronische myeloische Leukämie — State of the Art

  • CME-Topic
  • Published:
best practice onkologie Aims and scope

An Erratum to this article was published on 09 February 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Hehlmann R et al (2007) Chronic myeloid leukaemia. Lancet 370:342–350

    Article  CAS  PubMed  Google Scholar 

  2. Sokal JE et al (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49–61

    CAS  PubMed  Google Scholar 

  3. Hasford J et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850–858

    Article  CAS  PubMed  Google Scholar 

  4. Hasford J et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The Eutos score. Blood 118:686–692

    Article  CAS  PubMed  Google Scholar 

  5. Arber DA et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405

    Article  PubMed  Google Scholar 

  6. Baccarani M et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. O’Brien SG et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004

    Article  PubMed  Google Scholar 

  8. Hochhaus A et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054–1061

    Article  CAS  PubMed  Google Scholar 

  9. Weisberg E et al (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345–356

    Article  CAS  PubMed  Google Scholar 

  10. Hochhaus A et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 30:1044–1054.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. La Rosée P et al (2013) Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol 92:1345–1350

    Article  PubMed  Google Scholar 

  12. Hochhaus A, Kantarjian H (2013) The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol 139:1971–1984

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cortes JE et al (2016) Final 5-year study results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 34:2333–2340

    Article  PubMed  Google Scholar 

  14. Brümmendorf TH et al (2015) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 168:69–81

    Article  PubMed  Google Scholar 

  15. Cortes JE et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783–1796

    Article  CAS  PubMed  Google Scholar 

  16. Lipton JH et al (2016) Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 17:612–621

    Article  CAS  PubMed  Google Scholar 

  17. Hehlmann R et al (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29:1634–1642

    Article  CAS  PubMed  Google Scholar 

  18. Cortes JE et al (2010) Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28:424–430

    Article  CAS  PubMed  Google Scholar 

  19. Hochhaus A (2014) Optimizing tolerability of TKI therapy in CML. Blood 123:1284–1285

    Article  CAS  PubMed  Google Scholar 

  20. Steegmann JL et al (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30(8):1648–1671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Preudhomme C (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363:2511–2521

    Article  CAS  PubMed  Google Scholar 

  22. Simonsson B et al (2011) Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118:3228–3235

    Article  CAS  PubMed  Google Scholar 

  23. Burchert A et al (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28:1429–1435

    Article  CAS  PubMed  Google Scholar 

  24. Burchert A, et al (2015) Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia 29:1331–1335.

    Article  CAS  PubMed  Google Scholar 

  25. Mahon FX et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029–1035

    Article  CAS  PubMed  Google Scholar 

  26. Saußele S et al (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30:1638–1647

    Article  PubMed  PubMed Central  Google Scholar 

  27. Kantarjian HM et al (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117:1141–1145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. le Coutre PD et al (2012) Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26:1189–1194

    Article  PubMed  Google Scholar 

  29. Giles FJ et al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959–962

    Article  CAS  PubMed  Google Scholar 

  30. Hochhaus A et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200–1206

    Article  CAS  PubMed  Google Scholar 

  31. Shah NP et al (2010) Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232–240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Apperley JF et al (2009) Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The START A trial. J Clin Oncol 27:3472–3479

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cortes J et al (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207–3213

    Article  CAS  PubMed  Google Scholar 

  34. Hughes T et al (2009) Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 27:4204–4210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Müller MC et al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944–4953

    Article  PubMed  PubMed Central  Google Scholar 

  36. Saussele S et al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML study IV. Blood 115:1880–1885

    Article  CAS  PubMed  Google Scholar 

  37. Hehlmann R (2012) How I treat CML blast crisis. Blood 120:737–747

    Article  CAS  PubMed  Google Scholar 

  38. Cross NC et al (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172–2175

    Article  CAS  PubMed  Google Scholar 

  39. Hanfstein B et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096–2102

    Article  CAS  PubMed  Google Scholar 

  40. Hanfstein B et al (2014) Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 28:1988–1992

    Article  CAS  PubMed  Google Scholar 

  41. Hochhaus A, La Rosée P (2004) Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia 18:1321–1331

    Article  CAS  PubMed  Google Scholar 

  42. Soverini S et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118:1208–1215

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07740, Jena, Deutschland

    A. Hochhaus, E. Eigendorff, C. Fabisch & T. Ernst

Authors
  1. A. Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Eigendorff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Fabisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Ernst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Hochhaus.

Additional information

Einhaltung ethischer Richtlinien

Interessenkonflikt. Das Autorenteam gibt Folgendes an: Forschungsunterstützung (Fa. Novartis, Fa. BMS, Fa. Ariad, Fa. Pfizer, Fa. MSD).

Ein Erratum zu diesem Beitrag ist unter http://dx.doi.org/10.1007/s11654-017-0012-3 zu finden.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hochhaus, A., Eigendorff, E., Fabisch, C. et al. Chronische myeloische Leukämie — State of the Art. best practice onkologie 11, 48–57 (2016). https://doi.org/10.1007/s11654-016-0589-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-016-0589-y

Search

Navigation